Gempharmatech Co. Ltd. A
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides cust… Read more
Gempharmatech Co. Ltd. A - Asset Resilience Ratio
Gempharmatech Co. Ltd. A (688046) has an Asset Resilience Ratio of 23.95% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Gempharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Gempharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥670.25 Million | 23.95% |
| Total Liquid Assets | CN¥670.25 Million | 23.95% |
Asset Resilience Insights
- Good Liquidity Position: Gempharmatech Co. Ltd. A maintains a healthy 23.95% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Gempharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Gempharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Gempharmatech Co. Ltd. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Gempharmatech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.17% | CN¥467.34 Million | CN¥2.57 Billion | -6.58pp |
| 2023-12-31 | 24.74% | CN¥637.72 Million | CN¥2.58 Billion | -10.37pp |
| 2022-12-31 | 35.11% | CN¥791.24 Million | CN¥2.25 Billion | +15.59pp |
| 2021-12-31 | 19.52% | CN¥205.80 Million | CN¥1.05 Billion | +12.58pp |
| 2019-12-31 | 6.93% | CN¥26.92 Million | CN¥388.14 Million | -- |